Immunobiome Expands Recruitment of Top Talent in New Drug Development R&D and Financial Accounting... Launching Business Expansion

[Asia Economy Reporter Hyunseok Yoo] Immunobiome, a microbiome therapeutic research and development company, is publicly recruiting outstanding talent to expand its patient-customized microbe-based new drug development business.

On the 8th, Immunobiome announced that it is recruiting experienced and new employees at the Pohang Research Center for the following positions: ▲ R&D Team 1 (New Drug Development Institute, Microbial Cultivation & Fermentation) ▲ R&D Team 2 (New Drug Development Institute, In vitro & In vivo Efficacy Evaluation) ▲ R&D Planning (New Drug Development Institute) as team leaders and team members. The qualification requirements include a master's degree or higher in related fields such as life sciences, microbiology, immunology, molecular biology, cell biology, or biochemistry.

At the same time, experienced professionals are also being recruited for ▲ BD Team 1 (Technology Strategy) ▲ BD Team 2 (Clinical Development) ▲ Finance and Accounting (Management Support).

The application period is until the 30th of this month, and applications can be submitted online through the recruitment site 'Saramin.'

An Immunobiome official stated, "We hope to move forward with passionate and skilled talents to grow as a global leader in microbiome-targeted therapeutic development," adding, "We plan to support various systems such as stock options for all employees, flexible working hours, and remote work support systems to help develop each employee's career along with the company's growth."

Immunobiome was established in June 2019 as a microbiome-based new drug research and development company. It aims to develop new concept therapeutics targeting cancers, autoimmune diseases, organ transplant rejection, and neurological disorders that are difficult to treat with modern medicine. Through the development of patient-customized microbe-based new drugs that have fewer side effects and can enhance therapeutic effects when used in combination with existing drugs, the company seeks to contribute to human health.

This content was produced with the assistance of AI translation services.